Table I.
Category | ID | Description | FDR | Count |
---|---|---|---|---|
BP | GO:0006958 | Complement activation, classical pathway | 7.28×10−41 | 66 |
BP | GO:0002455 | Humoral immune response mediated by circulating immunoglobulin | 4.39×10−38 | 66 |
BP | GO:0006956 | Complement activation | 9.99×10−37 | 69 |
BP | GO:0072376 | Protein activation cascade | 4.04×10−35 | 72 |
BP | GO:0016064 | Immunoglobulin mediated immune response | 3.05×10−30 | 70 |
CC | GO:0019814 | Immunoglobulin complex | 2.36×10−23 | 32 |
CC | GO:0042571 | Immunoglobulin complex, circulating | 4.44×10−22 | 30 |
CC | GO:0005578 | Proteinaceous extracellular matrix | 7.54×10−17 | 76 |
CC | GO:0072562 | Blood microparticle | 3.36×10−16 | 50 |
CC | GO:0009897 | External side of plasma membrane | 1.74×10−13 | 58 |
MF | GO:0003823 | Antigen binding | 6.35×10−45 | 84 |
MF | GO:0004252 | Serine-type endopeptidase activity | 9.37×10−22 | 67 |
MF | GO:0008236 | Serine-type peptidase activity | 1.88×10−20 | 69 |
MF | GO:0017171 | Serine hydrolase activity | 4.34×10−20 | 69 |
MF | GO:0034987 | Immunoglobulin receptor binding | 1.38×10−19 | 29 |
Pathway | hsa00982 | Drug metabolism-cytochrome P450 | 6.63×10−04 | 17 |
Pathway | hsa04060 | Cytokine-cytokine receptor interaction | 6.63×10−04 | 39 |
Pathway | hsa05204 | Chemical carcinogenesis | 6.63×10−04 | 18 |
Pathway | hsa04976 | Bile secretion | 1.13×10−03 | 16 |
Pathway | hsa04978 | Mineral absorption | 1.41×10−03 | 13 |
BP, biological process; CC, cellular component; MF, molecular function; FDR, false discovery rate.